Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EndoCeutics Inc.
With
AMAG Pharmaceuticals, Inc.
Age
30–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Main criteria:
1. Natural, surgically- or treatment-induced postmenopausal women (non hysterectomized or hysterectomized) with breast cancer (stage 1 or 2) who is currently under treatment with an aromatase inhibitor and will remain on that treatment for the duration of the study.
2. Women between 30 and 80 years of age
3. Women having ≤5% of superficial cells on vaginal smear at baseline
4. Women having a vaginal pH above 5 at baseline
5. Women who have self-identified moderate or severe symptom(s) of vaginal atrophy
You may not be if
Main criteria:
1. Clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by medication
2. The administration of any investigational drug within 30 days of screening visit
Clareo Health | Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
